Logo image of AUTL

AUTOLUS THERAPEUTICS PLC (AUTL) Stock Fundamental Analysis

NASDAQ:AUTL - Nasdaq - US05280R1005 - ADR - Currency: USD

1.95  0 (0%)

After market: 1.9599 +0.01 (+0.51%)

Fundamental Rating

2

Overall AUTL gets a fundamental rating of 2 out of 10. We evaluated AUTL against 571 industry peers in the Biotechnology industry. The financial health of AUTL is average, but there are quite some concerns on its profitability. AUTL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AUTL has reported negative net income.
In the past year AUTL has reported a negative cash flow from operations.
In the past 5 years AUTL always reported negative net income.
In the past 5 years AUTL always reported negative operating cash flow.
AUTL Yearly Net Income VS EBIT VS OCF VS FCFAUTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.18%, AUTL is in the better half of the industry, outperforming 73.18% of the companies in the same industry.
With a decent Return On Equity value of -43.69%, AUTL is doing good in the industry, outperforming 69.27% of the companies in the same industry.
Industry RankSector Rank
ROA -25.18%
ROE -43.69%
ROIC N/A
ROA(3y)-40.3%
ROA(5y)-42%
ROE(3y)-94.04%
ROE(5y)-79.68%
ROIC(3y)N/A
ROIC(5y)N/A
AUTL Yearly ROA, ROE, ROICAUTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

AUTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AUTL Yearly Profit, Operating, Gross MarginsAUTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

AUTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AUTL has a worse debt to assets ratio.
AUTL Yearly Shares OutstandingAUTL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
AUTL Yearly Total Debt VS Total AssetsAUTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -0.66, we must say that AUTL is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.66, AUTL is doing good in the industry, outperforming 61.28% of the companies in the same industry.
AUTL has a Debt/Equity ratio of 0.52. This is a neutral value indicating AUTL is somewhat dependend on debt financing.
The Debt to Equity ratio of AUTL (0.52) is worse than 75.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -0.66
ROIC/WACCN/A
WACC9.01%
AUTL Yearly LT Debt VS Equity VS FCFAUTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 13.69 indicates that AUTL has no problem at all paying its short term obligations.
AUTL has a better Current ratio (13.69) than 87.03% of its industry peers.
A Quick Ratio of 13.69 indicates that AUTL has no problem at all paying its short term obligations.
AUTL has a Quick ratio of 13.69. This is amongst the best in the industry. AUTL outperforms 87.03% of its industry peers.
Industry RankSector Rank
Current Ratio 13.69
Quick Ratio 13.69
AUTL Yearly Current Assets VS Current LiabilitesAUTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AUTL have decreased strongly by -24.49% in the last year.
The Revenue for AUTL has decreased by -73.30% in the past year. This is quite bad
AUTL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.79% yearly.
EPS 1Y (TTM)-24.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.23%
Revenue 1Y (TTM)-73.3%
Revenue growth 3Y-0.43%
Revenue growth 5Y3.79%
Sales Q2Q%-100%

3.2 Future

AUTL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.33% yearly.
Based on estimates for the next years, AUTL will show a very strong growth in Revenue. The Revenue will grow by 198.62% on average per year.
EPS Next Y22.01%
EPS Next 2Y12.18%
EPS Next 3Y10.31%
EPS Next 5Y17.33%
Revenue Next Year487.76%
Revenue Next 2Y315.46%
Revenue Next 3Y288.43%
Revenue Next 5Y198.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AUTL Yearly Revenue VS EstimatesAUTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AUTL Yearly EPS VS EstimatesAUTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AUTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUTL Price Earnings VS Forward Price EarningsAUTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUTL Per share dataAUTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.18%
EPS Next 3Y10.31%

More info and screens

0

5. Dividend

5.1 Amount

AUTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL (2/21/2025, 8:02:17 PM)

After market: 1.9599 +0.01 (+0.51%)

1.95

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners83.99%
Inst Owner Change-96.56%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap518.94M
Analysts85.88
Price Target10.38 (432.31%)
Short Float %4.27%
Short Ratio6.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.42%
Min EPS beat(2)-41.83%
Max EPS beat(2)-11.01%
EPS beat(4)0
Avg EPS beat(4)-113.84%
Min EPS beat(4)-327.81%
Max EPS beat(4)-11.01%
EPS beat(8)2
Avg EPS beat(8)-54.95%
EPS beat(12)4
Avg EPS beat(12)-36.49%
EPS beat(16)7
Avg EPS beat(16)-25.75%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-90.11%
Min Revenue beat(4)-100%
Max Revenue beat(4)-60.43%
Revenue beat(8)2
Avg Revenue beat(8)-24.39%
Revenue beat(12)3
Avg Revenue beat(12)106.21%
Revenue beat(16)5
Avg Revenue beat(16)124.67%
PT rev (1m)-1.76%
PT rev (3m)-5.41%
EPS NQ rev (1m)7.89%
EPS NQ rev (3m)7.89%
EPS NY rev (1m)-2.96%
EPS NY rev (3m)-11.74%
Revenue NQ rev (1m)-15.23%
Revenue NQ rev (3m)-15.23%
Revenue NY rev (1m)-20.1%
Revenue NY rev (3m)-17.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 305.62
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0.01
BVpS1.79
TBVpS1.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.18%
ROE -43.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.3%
ROA(5y)-42%
ROE(3y)-94.04%
ROE(5y)-79.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 167.78%
Cap/Sales 732.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.69
Quick Ratio 13.69
Altman-Z -0.66
F-Score3
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)139.39%
Cap/Depr(5y)216.5%
Cap/Sales(3y)399.23%
Cap/Sales(5y)538.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.23%
EPS Next Y22.01%
EPS Next 2Y12.18%
EPS Next 3Y10.31%
EPS Next 5Y17.33%
Revenue 1Y (TTM)-73.3%
Revenue growth 3Y-0.43%
Revenue growth 5Y3.79%
Sales Q2Q%-100%
Revenue Next Year487.76%
Revenue Next 2Y315.46%
Revenue Next 3Y288.43%
Revenue Next 5Y198.62%
EBIT growth 1Y-4.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.76%
EBIT Next 3Y6.76%
EBIT Next 5Y13.89%
FCF growth 1Y-73.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.71%
OCF growth 3YN/A
OCF growth 5YN/A